FR 190997

structure given in first source

Also Known As:

8-(2,6-dichloro-3-(N-((E)-4-(N-methylcarbamoyl)cinnamidoacetyl)-N-methyl-amino)benzyloxy)-2-methyl-4-(2-pyridylmethoxy)quinoline; FR-190997; FR190997

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - FR 190997: 5

Experts

1.	Afratis, Konstantinos: 1 article (01/2021)
2.	Gavras, Haralambos: 1 article (01/2021)
3.	Karamanos, Nikos K: 1 article (01/2021)
4.	Koutsakis, Christos: 1 article (01/2021)
5.	Leonardi, Sofia: 1 article (01/2021)
6.	Papaioannou, Dionissios: 1 article (01/2021)
7.	Piperigkou, Zoi: 1 article (01/2021)
8.	Rassias, Gerasimos: 1 article (01/2021)
9.	Rigopoulou, Dionisia: 1 article (01/2021)
10.	Vachlioti, Eleanna: 1 article (01/2021)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2023 - "Consequently, we initiated a program aiming primarily at synthesizing adequate quantities of FR-190997 to support further in vitro and in vivo studies toward its repurposing for various cancers and, in parallel, enable the generation of novel FR-190997 analogs for an SAR study. "
2.	Hypotension (Low Blood Pressure) 01/01/2000 - "An intra-arterial (IA) injection of FR190997 (0.3 to 30 nmol/kg) caused dose-dependent hypotension in conscious Sprague-Dawley rats. " 12/01/1999 - "The potency of FR190997 was weaker than that of bradykinin, when compared with the maximal hypotension. "
3.	Breast Neoplasms (Breast Cancer) 01/15/2021 - "We synthesized and assessed the highly selective and potent B2R partial agonist FR-190997 in MCF-7 and MDA-MBA-231 breast cancer lines and found it possessed significant antiproliferative activity (IC50 2.14 and 0.08 μΜ, respectively). " 05/01/2023 - "FR-190997 elicited an EC50 of 80 nM in the triple-negative breast cancer cell line MDA-MB-231, a much superior performance to that exhibited by most approved breast cancer drugs. "
4.	Triple Negative Breast Neoplasms 05/01/2023 - "FR-190997 elicited an EC50 of 80 nM in the triple-negative breast cancer cell line MDA-MB-231, a much superior performance to that exhibited by most approved breast cancer drugs. "
5.	Hypertension (High Blood Pressure) 01/01/2000 - "We tested whether FR190997, a nonpeptide B(2) agonist, prevented the development of hypertension in young spontaneously hypertensive rats (SHR), which secrete less kallikrein into the urine than do Wistar-Kyoto rats. "

Related Drugs and Biologics

1.	Bradykinin B2 Receptor
2.	Solutions
3.	Peptides (Polypeptides)
4.	Kallikreins (Kallikrein)
5.	Bradykinin
6.	icatibant
7.	2,5-dichloro-4-bromophenol (B 2)

Related Therapies and Procedures

1.	Subcutaneous Injections